Ibrance
Provider 
Founded 1849
Sells To Non-Profit
Pricing Model Recurring
Ownership Private
Pfizer offers Ibrance
Product
Ibrance (palbociclib) is Pfizer's first-in-class oral CDK4/6 inhibitor for HR-positive breast cancer.
- Currently Offered
Ibrance (palbociclib) is Pfizer's first-in-class oral CDK4/6 inhibitor for HR-positive breast cancer.
Ibrance is an oral small-molecule inhibitor of CDK4 and CDK6, the kinases that propel cell-cycle progression from G1 into S phase. It became the first CDK4/6 inhibitor to win U.S. approval in 2015 and is indicated for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer given alongside endocrine partners such as letrozole or fulvestrant.
As the category-defining CDK4/6 inhibitor, Ibrance established the current standard of care that newer CDK4-selective candidates now aim to improve upon, particularly by attempting to reduce the neutropenia that accompanies combined CDK4 and CDK6 blockade.
Adds products that compete with one of Ibrance’s direct competitors but not with Ibrance itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | Ibrance | ARTS-023 / AVZO-023 (CDK4 selective inhibitor) | Verzenio | |
|---|---|---|---|---|
| Linked Through | — | Direct competitor | ARTS-023 / AVZO-023 (CDK4 selective inhibitor) | |
| Provider | |  |  | |
| Founded | 1849 | 2020 | 1876 | |
| Sells To | Non-Profit | Enterprise | Consumers, Enterprise | |
| Pricing Model | Recurring | Recurring, Software | Recurring, Software, Transactional | |
| Ownership | Private | Private | Public |
Provider
Founded 1849
Sells To Non-Profit
Pricing Model Recurring
Ownership Private
Provider
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Linked Through ARTS-023 / AVZO-023 (CDK4 selective inhibitor)
Provider
Founded 1876
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public
Verzenio (abemaciclib) is Eli Lilly's oral CDK4/6 inhibitor for HR-positive breast cancer.
Atirmociclib is Pfizer's investigational oral CDK4-selective inhibitor for HR-positive breast cancer.
Verzenio (abemaciclib) is Eli Lilly's oral CDK4/6 inhibitor for HR-positive breast cancer.
Atirmociclib is Pfizer's investigational oral CDK4-selective inhibitor for HR-positive breast cancer.